Harmonised high throughput microsomal stability assay

Andersson, 2004, An evaluation of the in vitro metabolism data for predicting the clearance and drug–drug interaction potential of CYP2C9 substrates, Drug Metabolism and Disposition, 32, 715, 10.1124/dmd.32.7.715 Austin, 2002, The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties, Drug Metabolism and Disposition, 30, 1497, 10.1124/dmd.30.12.1497 Baranczewski, 2006, Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development, Pharmacology Reports, 58, 453 Bjornsson, 2003, The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective, Drug Metabolism and Disposition, 31, 815, 10.1124/dmd.31.7.815 Bland, 1986, Statistical methods for assessing agreement between two methods of clinical measurement, Lancet, 327, 307, 10.1016/S0140-6736(86)90837-8 Bonn, 2016, Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: Comparison of a primary hepatocyte/stromal cell co-culture with plated primary hepatocytes and HepaRG, Drug Metabolism and Disposition, 44, 527, 10.1124/dmd.115.067769 Busby, 1999, Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450, Drug Metabolism and Disposition, 27, 246 Carlile, 1999, Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans, British Journal of Clinical Pharmacology, 47, 625, 10.1046/j.1365-2125.1999.00935.x Cavalla, 2003, The extended pharmaceutical enterprise, Drug Discovery Today, 8, 267, 10.1016/S1359-6446(03)02634-5 Chauret, 1998, Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes, Drug Metabolism and Disposition, 26, 1 Clark, 2007, Outsourcing lead optimization: Constant change is here to stay, Drug Discovery Today, 12, 62, 10.1016/j.drudis.2006.11.005 Clark, 2011, Outsourcing lead optimization: The eye of the storm, Drug Discovery Today, 16, 147, 10.1016/j.drudis.2010.11.012 Clark, 2004, Outsourcing lead optimisation—The quiet revolution, Drug Discovery Today, 9, 492, 10.1016/S1359-6446(04)03102-2 Di, 2008, Applications of high throughput microsomal stability assay in drug discovery, Combinatorial Chemistry and High Throughput Screening, 11, 469, 10.2174/138620708784911429 Di, 2012, A novel relay method for determining low-clearance values, Drug Metabolism and Disposition, 40, 1860, 10.1124/dmd.112.046425 Easterbrook, 2001, Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes, Drug Metabolism and Disposition, 29, 141 Fonsi, 2008, High-throughput microsomal stability assay for screening new chemical entities in drug discovery, Journal of Biomolecular Screening, 13, 862, 10.1177/1087057108323911 Hickman, 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities, Drug Metabolism and Disposition, 26, 207 Hutzler, 2003, Inhibition of cytochrome P450 2D6: Structure-activity studies using a series of quinidine and quinine analogues, Chemical Research in Toxicology, 16, 450, 10.1021/tx025674x Jenkins, 2004, Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries, Journal of Pharmaceutical and Biomedical Analysis, 34, 989, 10.1016/j.jpba.2003.08.001 Jia, 2007, The conduct of drug metabolism studies considered good practice (II): In vitro experiments, Current Drug Metabolism, 8, 822, 10.2174/138920007782798207 Kariv, 2001, Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism, Journal of Biomolecular Screening, 6, 91, 10.1177/108705710100600205 Kassel, 2004, Applications of high-throughput ADME in drug discovery, Current Opinion in Chemical Biology, 8, 339, 10.1016/j.cbpa.2004.04.015 Kishida, 2008, Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats, Journal of Toxicological Sciences, 33, 447, 10.2131/jts.33.447 Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nature Reviews Drug Discovery, 3, 711, 10.1038/nrd1470 Löfgren, 2008, Metabolism of human cytochrome P450 marker substrates in mouse: A strain and gender comparison, Xenobiotica, 34, 811, 10.1080/00498250412331285463 Lu, 2010 Maenpaa, 1998, Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone, Pharmacogenetics, 8, 137 Mazur, 2009, Contrasting influence of NADPH and a NADPH-regenerating system on the metabolism of carbonyl-containing compounds in hepatic microsomes, Drug Metabolism and Disposition, 37, 1801, 10.1124/dmd.109.027615 Naritomi, 2001, Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans, Drug Metabolism and Disposition, 29, 1316 Obach, 1999, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes, Drug Metabolism and Disposition, 27, 1350 Plant, 2004, Strategies for using in vitro screens in drug metabolism, Drug Discovery Today, 9, 328, 10.1016/S1359-6446(03)03019-8 Richmond, 2010, Interstrain differences of in vitro metabolic stability and impact on early drug discovery, Journal of Pharmacological Sciences, 99, 4463, 10.1002/jps.22179 Riley, 2004, Metabolic screening in vitro: Metabolic stability, CYP inhibition and induction, Drug Discovery Today: Technologies, 1, 365, 10.1016/j.ddtec.2004.10.008 Riley, 2002, The influence of DMPK as an integrated partner in modern drug discovery, Current Drug Metabolism, 3, 527, 10.2174/1389200023337135 Riley, 2005, A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes, Drug Metabolism and Disposition, 33, 1304, 10.1124/dmd.105.004259 Saito, 2004, Strain differences in diazepam metabolism at its three metabolic sites in Sprague-Dawley, Brown Norway, Dark Agouti, and Wistar strain rats, Drug Metabolism and Disposition, 32, 959 Taylor, 2006 Tucker, 2001, Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential—Towards a consensus, British Journal of Clinical Pharmacology, 52, 107, 10.1046/j.0306-5251.2001.temp.1441.x Van De Waterbeemd, 2003, ADMET in silico modelling: Towards prediction paradise?, Nature Reviews Drug Discovery, 2, 192, 10.1038/nrd1032 Walters, 2012, Going further than Lipinski's rule in drug design, Expert Opinion on Drug Discovery, 7, 99, 10.1517/17460441.2012.648612 Williams, 2012 Yasgar, 2010